US FDA Requires GLP-1 RA Drugmakers to Add Potential Vision Loss Risk Warning

11:42 PM EST, 11/09/2026 (MT Newswires) -- The US Food and Drug Administration is mandating that manufacturers of glucagon-like peptide-1 receptor agonist, or GLP-1 RA, medications update product labels to warn of a potential increased risk of non-arteritic anterior ischemic optic neuropathy, a rare but serious eye condition. The regulator advised patients and healthcare providers to be aware of the potential risk associated with the use of GLP-1 RAs, which are widely used to treat people with type 2 diabetes or to lose weight, according to a Monday notice. Novo Nordisk (NOVO-B.CO) and Eli Lilly (LLY.F) are among the drugmakers with FDA-approved GLP-1 RAs. Novo Nordisk and Eli Lilly did not immediately respond to a request for comment from MT Newswires.